Do women produce testosterone, and what happens when levels decline?
Women’s bodies produce testosterone in the ovaries and adrenal glands. In premenopausal women, testosterone levels range from approximately 15 to 70 ng/dL, substantially lower than male ranges (300 to 1,000 ng/dL) but physiologically significant. Testosterone in women contributes to libido, muscle mass maintenance, bone density, mood, and cognitive function.
Testosterone levels in women decline progressively from the mid-twenties onward. The decline accelerates at menopause, particularly following surgical menopause (bilateral oophorectomy), where the primary source of female testosterone production is removed abruptly. By the late forties and fifties, many women’s testosterone levels are less than half of their peak values.
Whether the symptoms many women attribute to menopause — reduced libido, fatigue, loss of muscle tone, low mood — are driven partly by testosterone decline (alongside estrogen and progesterone changes) is an active clinical question. The 2019 Global Consensus Statement concluded that the evidence supports testosterone therapy for postmenopausal women with hypoactive sexual desire disorder (HSDD).
What does the 2019 Global Consensus Statement say about female TRT?
The Global Consensus Position Statement on the Use of Testosterone Therapy for Women, published in the Journal of Clinical Endocrinology & Metabolism and endorsed by major international endocrinology, sexual medicine, and menopause societies, represents the current authoritative clinical position on female TRT.
Its key conclusions:
- Established indication: Testosterone therapy has the best evidence for postmenopausal women with HSDD — reduced sexual desire causing personal distress — and is recommended when estrogen therapy alone has not addressed this symptom.
- Physiological dosing is essential: Testosterone therapy for women should aim to restore blood levels to the normal physiological range for women, not to male ranges. Supraphysiological dosing is associated with androgenic side effects including acne, increased body and facial hair, and voice changes.
- Safety at physiological doses: The statement concluded that short-to-medium-term testosterone therapy at physiological female doses does not appear to negatively affect cardiovascular risk, breast cancer risk, or other safety parameters — while acknowledging that long-term data is still being gathered.
- No approved product: The statement noted the absence of a testosterone product specifically approved for women in most countries, meaning clinicians prescribe compounded or off-label low-dose formulations. This is a regulatory gap, not an evidence gap.
The absence of an FDA-approved product for women is a regulatory gap, not an evidence gap — the clinical case is well established.
What can low-dose testosterone in women be used for beyond HSDD?
While HSDD is the most evidence-supported indication, clinicians who specialize in hormone health often apply low-dose testosterone in women for broader purposes, understanding that the evidence base for some of these applications is still developing.
- Musculoskeletal support: Testosterone contributes to muscle protein synthesis and bone density maintenance. Some evidence supports a role for testosterone in reducing age-related muscle loss (sarcopenia) in women, though this is an area of active research rather than established protocol.
- Fatigue and energy: Patient-reported improvements in energy and sense of vitality are commonly described in women on testosterone therapy. These are harder to study rigorously than libido, which can be assessed with validated scales, and the evidence here is more observational.
- Cognitive symptoms: Some women report improvements in focus and cognitive clarity. The mechanistic basis is plausible (testosterone receptors exist in the brain), but clinical trial evidence specifically in women is limited.
- Mood support: Testosterone has mild antidepressant properties in preclinical models, and some clinical data in women suggests mood benefit, though this overlaps significantly with the libido and energy improvements and is difficult to isolate.
A qualified clinician evaluates which symptoms may be related to testosterone levels and which are more likely driven by other hormonal or non-hormonal factors — an assessment that requires labs, a clinical history, and individualized judgment.
How does female TRT differ from male testosterone protocols?
Female TRT is a fundamentally different treatment from male TRT in dose, administration method, and clinical goals.
| Parameter | Female TRT | Male TRT |
|---|---|---|
| Testosterone target range | ~15–70 ng/dL (physiological female range) | ~400–700 ng/dL (mid-normal male range) |
| Typical dose | 0.5–1 mg/day (topical) | 100–200 mg/week (injectable) |
| Primary route | Compounded topical cream or gel | Injectable (IM or SQ) or topical |
| FDA-approved product available? | No (regulatory gap; compounded formulations used) | Yes (testosterone cypionate, enanthate, etc.) |
| Primary evidence-backed indication | HSDD in postmenopausal women (2019 Global Consensus) | Hypogonadism (Endocrine Society 2018 guideline) |
- Dose: Female TRT doses are typically 10 to 20 times lower than male doses. A common starting dose for women is 0.5 to 1 mg of testosterone daily — a fraction of the 50 to 100 mg daily doses used in male protocols. The goal is restoration to the physiological female range, not the male range.
- Administration route: Topical compounded cream or gel is the most common delivery method for women, often applied to the inner arm or labia minora for local absorption. Injectable testosterone is less commonly used in women due to the difficulty of achieving precise low-dose delivery. Pellet implants are used by some specialist clinicians.
- Monitoring frequency: Labs are typically checked 6 to 8 weeks after initiation and then every 3 to 6 months once levels are stable. The target range is the upper-normal female range on the assay used by your laboratory.
- Androgenic side effect threshold: Women have lower baseline androgen levels, so the side effect threshold for androgenic symptoms (acne, hair growth) is reached at much lower absolute testosterone levels than in men. This is why precise dosing and monitoring are essential — small overdoses relative to the target range have noticeable effects.
What labs are needed before and during therapy?
Clinician-supervised TRT for women requires lab evaluation before initiation and at regular intervals during treatment. This is not optional — dosing without baseline labs leads to either under-treatment (not reaching therapeutic levels) or over-treatment (risking androgenic side effects or health risks).
Standard baseline labs typically include:
- Total and free testosterone
- Sex hormone-binding globulin (SHBG) — which affects free testosterone bioavailability
- Estradiol and progesterone (to assess the full hormonal picture)
- FSH and LH (to characterize menopausal status)
- Metabolic panel, lipids, and CBC
- Hematocrit (elevated hematocrit can occur with testosterone therapy)
Monitoring labs during therapy track testosterone levels to confirm physiological range dosing, plus ongoing lipids and hematocrit. The frequency is determined by your clinician based on dose and response.
Frequently asked questions
What is TRT for women?
TRT for women refers to low-dose testosterone replacement therapy in women — typically at doses 10 to 20 times lower than those used in male TRT protocols. Women produce testosterone naturally in the ovaries and adrenal glands, and levels decline with age and at menopause. Low-dose supplementation aims to restore testosterone to the physiological range for women, not to approach male levels.
Is testosterone therapy safe for women?
The 2019 Global Consensus Statement, endorsed by major endocrinology and sexual medicine societies, concluded that testosterone therapy is safe and effective for postmenopausal women with hypoactive sexual desire disorder (HSDD) when dosed to maintain blood levels in the physiological female range. Safety monitoring with regular labs is required. Supraphysiological dosing carries risks including virilization, cardiovascular effects, and other androgenic side effects.
What symptoms may indicate low testosterone in women?
Symptoms potentially associated with low testosterone in women include reduced libido, fatigue, decreased muscle mass and strength, low mood, and reduced sense of wellbeing. These symptoms overlap significantly with other hormonal and non-hormonal conditions, so lab evaluation is necessary to confirm low levels before attributing symptoms to testosterone deficiency.
What labs are needed for TRT in women?
Before initiating TRT, baseline labs typically include total testosterone, free testosterone, SHBG (sex hormone-binding globulin), estradiol, FSH, and LH, along with a metabolic panel. Ongoing monitoring while on therapy tracks testosterone levels to verify physiological range dosing, along with hematocrit, lipids, and liver enzymes at clinician-specified intervals.
What forms of testosterone are used in female TRT?
Low-dose testosterone for women is typically administered as compounded topical cream or gel, or as subcutaneous pellets. Oral testosterone is generally not used due to liver metabolism concerns. The specific formulation, dose, and delivery method are determined by the prescribing clinician based on labs and clinical goals.
How is female TRT different from male TRT?
Female TRT uses significantly lower doses, targeting the physiological female testosterone range (approximately 15 to 70 ng/dL) rather than the male range (300 to 1000 ng/dL). The administration method differs — women more commonly use topical preparations than injections. Monitoring thresholds and androgenic risk tolerance also differ between male and female protocols.